Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by State Street Corp

State Street Corp reduced its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 3.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,165,182 shares of the biopharmaceutical company’s stock after selling 46,127 shares during the quarter. State Street Corp’s holdings in Vanda Pharmaceuticals were worth $5,465,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in VNDA. Meeder Asset Management Inc. purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $39,000. ORG Wealth Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth $40,000. China Universal Asset Management Co. Ltd. raised its position in shares of Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 4,374 shares during the period. XTX Topco Ltd purchased a new stake in Vanda Pharmaceuticals during the second quarter valued at about $75,000. Finally, Intech Investment Management LLC purchased a new position in Vanda Pharmaceuticals in the third quarter valued at approximately $84,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA opened at $4.81 on Friday. The stock has a fifty day moving average of $4.86 and a 200-day moving average of $5.18. The company has a market capitalization of $280.46 million, a PE ratio of -17.18 and a beta of 0.76. Vanda Pharmaceuticals Inc. has a one year low of $3.46 and a one year high of $6.75.

Analyst Ratings Changes

Several brokerages recently commented on VNDA. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Vanda Pharmaceuticals in a report on Monday, December 23rd. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a report on Friday. They set a “hold” rating on the stock.

Insider Transactions at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 8.90% of the stock is currently owned by insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.